CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionWalleye Capital LLC
Latest Disclosed Ownership915 shares
Latest Disclosed Value $ 43,527
Walleye Capital LLC ownership in CRSP / CRISPR Therapeutics AG

On May 13, 2026 - Walleye Capital LLC filed a 13F-HR/A form disclosing ownership of 915 shares of CRISPR Therapeutics AG (US:CRSP) valued at $43,527 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of CRISPR Therapeutics AG. The current value of the position is $47,434 USD.

Walleye Capital LLC has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 41,700 of underlying shares valued at $1,983,669 USD and put options representing 6,400 of underlying shares valued at $304,448 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 915 915 44 0.0002
2026-05-08 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 915 915 44 0.0002
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -25,131 -100.00 0 -100.00
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 25,131 -133,304 -84.14 1,222 -77.33 0.0047
2025-05-14 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 158,435 142,908 920.38 5,392 782.32 0.0243
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 15,527 15,122 3,733.83 611 3,115.79 0.0015
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 405 -331 -44.97 19 -51.28 0.0000
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 736 144 24.32 40 -2.50 0.0001
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 592 592 40 0.0001
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -32,358 -100.00 0 -100.00
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 32,358 32,358 1,315 0.0240
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -1,555 -100.00 0 -100.00
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,555 1,555 64 0.0038
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 41,700 114.95 1,984 94.99 n/a n/a n/a
2026-05-08 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 41,700 1,984 n/a n/a n/a
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 19,400 108.60 1,017 68.94 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 9,300 -71.65 603 -62.26 n/a n/a n/a
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 32,800 81.22 1,595 159.35 n/a n/a n/a
2025-05-14 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 18,100 -52.37 616 -58.86 n/a n/a n/a
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 38,000 375.00 1,496 298.67 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 8,000 -82.30 376 -84.64 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 45,200 -6.61 2,441 -25.99 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 48,400 103.36 3,299 121.49 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 23,800 16.67 1,490 60.97 n/a n/a n/a
2023-11-21 2023-09-30 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 20,400 -10.53 926 -27.68 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 20,400 926 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 22,800 0.00 1,280 24.05 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 22,800 -22.71 1,031 -14.01 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 29,500 54.45 1,199 -3.93 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 19,100 1,248 n/a n/a n/a
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 9,600 31.51 394 14.53 n/a n/a n/a
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 7,300 -6.41 344 23.30 n/a n/a n/a
2019-08-14 2019-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 7,800 279 n/a n/a n/a
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 7,800 279 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 6,400 -52.24 304 -56.70 n/a n/a n/a
2026-05-08 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 6,400 304 n/a n/a n/a
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 13,400 69.62 703 37.38 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 7,900 -90.71 512 -87.64 n/a n/a n/a
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 85,000 -7.61 4,134 32.08 n/a n/a n/a
2025-05-14 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 92,000 165.13 3,131 129.30 n/a n/a n/a
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 34,700 402.90 1,366 321.30 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 6,900 2.99 324 -10.25 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 6,700 -53.47 362 -63.20 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 14,400 -53.55 982 -49.43 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 31,000 44.86 1,941 99.79 n/a n/a n/a
2023-11-21 2023-09-30 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 21,400 0.00 971 -19.15 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 21,400 971 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 21,400 45.58 1,201 80.87 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 14,700 24.58 665 38.62 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 11,800 6.31 480 -33.93 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 11,100 725 n/a n/a n/a
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 8,700 521.43 357 440.91 n/a n/a n/a
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 1,400 0.00 66 32.00 n/a n/a n/a
2019-08-14 2019-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 1,400 50 n/a n/a n/a
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 1,400 50 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.